Observational Study
Copyright ©The Author(s) 2016.
World J Hepatol. May 28, 2016; 8(15): 649-658
Published online May 28, 2016. doi: 10.4254/wjh.v8.i15.649
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 The flow of the hepatitis C virus disease progression model. HCC: Hepatocellular carcinoma.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Age and gender distribution of anti-hepatitis C virus prevalence, Argentina, 2013. HCV: Hepatitis C virus.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Model inputs for scenarios 1 and 2. SVR: Sustained virologic response; G1: Genotype 1.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Total number of viremic hepatitis C virus cases (with uncertainty intervals) according to year, 1950 to 2030.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Number of viremic hepatitis C virus cases, in total and according to disease stage. F: Fibrosis stage; HCC: Hepatocellular carcinoma.
Figure 6
Open in New Tab Full Size Figure Download Figure
Figure 6 Proportion of all viremic hepatitis C virus cases according to disease stage, 1950 to 2030. Decomp: Decompensated; F: Fibrosis stage; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus.
Figure 7
Open in New Tab Full Size Figure Download Figure
Figure 7 Selected hepatitis C virus-related outcomes by scenario - Argentina, 2013-2030. Scenario 1: Increased treatment efficacy; Scenario 2: Increased treatment efficacy and increased annual diagnosed/treated populations; HCC: Hepatocellular carcinoma.